Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
about
Immunotherapy for metastatic renal cell carcinomaA comprehensive overview of targeted therapy in metastatic renal cell carcinomaAxitinib for the management of metastatic renal cell carcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsSunitinib in the treatment of metastatic renal cell carcinomaImmunotherapy for metastatic renal cell carcinoma.Adjuvant therapy for renal cell carcinoma: past, present, and futureEconomic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcomeSunitinib for metastatic renal cell carcinoma.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.TroVax(®) vaccine therapy for renal cell carcinoma.Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Current Management Options in Metastatic Renal Cell Cancer.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer.A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function.[Metastatic renal cell carcinoma: primary and follow-up treatment].Rho GDP dissociation inhibitor-β in renal cell carcinoma.The current status of immunobased therapies for metastatic renal-cell carcinoma.Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.NierenzellkarzinomCytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients' Blood using Hydrogel-based Cell Block Formation
P2860
Q24186688-2E04AFDF-1D51-476E-A4CC-466CA17F4975Q24606852-033C212B-BEC4-4209-97AD-A7C75E44A3A1Q24613720-03EE5318-4137-4A70-B254-A23EFEFE13A7Q26852437-42738EE0-6408-44EA-8EFA-167349D9D33BQ27023770-3781DD42-854C-4294-AD6E-18FAFFBA26E2Q28072057-7E148D30-0C87-4667-97FC-9783F15B2E0EQ30234458-82104ABB-717B-4D74-BE52-DD84967F2F25Q34005127-C23097C4-D7AB-4086-8E94-50584925868FQ34193184-DF1FB037-0B60-4D77-A5B8-06DF00B47C8DQ35061982-BA67284E-52E5-4B1A-BCF2-40A5BDFEB028Q35163926-A2B7EA3E-3E2B-4BAA-B050-9E613BF7D0A8Q36689013-C23AA65F-8A50-4EB7-9BA7-A4447289463FQ37797460-D9B53E1E-1105-4651-90DD-E17F7720A22DQ37838448-94952BE1-CC3B-4B68-B8CC-ED472B760AC4Q37965748-FFBF101C-655A-49F9-9347-194A52C8B077Q37997462-D4F919C2-C63D-4F56-8326-34F83F57FD88Q38103580-85920BD2-CD20-47F2-9FA3-5CEBC92F10FEQ38233353-951CBC5D-046E-439A-B0F5-41817A029407Q38662325-09B45B2F-A6A8-4C8A-94E5-E689248A3BC9Q38799848-C418AA97-83F3-4D7A-A11E-A764E512B5AEQ38961755-CEE8B3EF-551F-4579-BC5E-B1E520A81940Q39167898-54F08D21-6547-4F59-85A6-571B767E8787Q39296942-4D435156-5AE0-44F5-8F1F-537DCF457E87Q41472778-2C4FDFB0-2E23-45F5-BEC4-529BC1EB7CEDQ41856342-4650A7B3-506C-4171-A477-7145C2634B39Q41898172-0AC1524B-E47E-4C43-BB76-B1119DF1EBA5Q42634225-3129FF4B-02C1-49E7-A44E-12B596860486Q45736434-A25AFAFA-EF65-4FA7-8A8C-98EF22F7BA19Q46099736-9ED9D6C1-C967-490F-9CFF-311C6C9EA876Q47096248-29CE5969-224B-4FF6-832E-9B5C74E4501AQ47097756-594C18C3-6088-441B-B36B-B677E5605774Q47835640-6E8077EE-EDED-4694-87B7-5C52985A4E17Q48556269-29F7AFFF-575D-4896-BBDD-06465E0DE5F1Q51112501-009DEC55-2210-425C-89A0-52C5B61DE85FQ56639125-938D0E33-5FE4-481D-9FA0-CAFB5F9B31FDQ57472749-561E197A-0CD9-4452-9CD3-C225BB3ECD8E
P2860
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@ast
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@en
type
label
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@ast
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@en
prefLabel
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@ast
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@en
P2093
P2860
P1433
P1476
Interferon alfa-2a versus comb ...... n open-label randomised trial.
@en
P2093
Barry Hancock
Clare L Griffin
Jozef Mardiak
Lynda Pyle
Mahesh K B Parmar
Martin E Gore
Michael Aitchison
Nicholas James
Peter F A Mulders
Poulam M Patel
P2860
P304
P356
10.1016/S0140-6736(09)61921-8
P407
P577
2010-02-10T00:00:00Z